Express Scripts finds generic antidepressant users as adherent as brand-name counterparts
ST. LOUIS — Patients who take generic antidepressants will remain as adherent as those who take brand-name drugs to treat the condition, according to a new study.
The study, conducted by Express Scripts and published in the Journal of Managed Care Pharmacy, found patients starting generic selective serotonin reuptake inhibitors and generic selective norepinephrine reuptake inhibitors had a discontinuation rate of 44.2%, compared with 46.8% among those on brand-name SSRIs and SNRIs.
However, drug costs for those starting on generics were almost 50% lower. Similarly, total healthcare costs were about 20% lower — an average of $3,660 in patients starting on a generic, compared with $4,587 for those starting on a brand-name drug.
The study analyzed antidepressant usage from more than 16,000 patient records in MarketScan, a database of integrated pharmacy and medical claims from commercially insured patients.
Trial date set for generic Copaxone litigation
JERUSALEM — Teva on Tuesday said that a trial date has been set for its ongoing patent infringement litigation against several drug makers.
Teva said the U.S. District Court for the Southern District of New York will commence proceedings Sept. 7. Teva’s litigation is against Momenta Pharmaceuticals/Sandoz and Mylan Pharmaceuticals/Mylan/Natco Pharma regarding their purported generic versions of Copaxone (glatiramer acetate injection).
"We are very pleased to have a trial date as we are confident we will prevail in this litigation,” said Richard Egosi, Teva’s chief legal officer. “Teva remains committed to vigorously defending its intellectual property rights against infringement.”
Heather Bresch, Robert Cindrich join Mylan’s board
PITTSBURGH — Mylan’s board of directors now includes the drug maker’s president.
Mylan said its board of directors now includes Mylan president Heather Bresch and Robert Cindrich, who currently serves as senior adviser to the office of the president at the University of Pittsburgh Medical Center, a global health enterprise.
With the additions of Bresch and Cindrich, Mylan’s board now has 11 members.